Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Tscherner, G. Kovacs, F. Fruhwald, R. Maier, B. Obermayer-Pietsch, A. Avian, V. Foris, H. Olschewski (Graz, Austria). The proANP increase during exercise may predict the PAP increase in connective tissue disease patients at risk of PAH. Eur Respir J 2012; 40: Suppl. 56, 3923

Member's Comments

No comment yet.

Related content which might interest you: Does lung function predict response to therapy in PAH associated with connective tissue disease? Source: Annual Congress 2012 - Pulmonary circulation: clinical end-points and clinical physiology Year: 2012 Lower DHEA-S levels predict disease and worse outcomes in post-menopausal women with idiopathic, connective tissue disease- and congenital heart disease-associated pulmonary arterial hypertension Source: Eur Respir J, 51 (6) 1800467; 10.1183/13993003.00467-2018 Year: 2018 Increased risk of peripheral arterial disease in individuals with COPD Source: International Congress 2017 – Prevalence, prognosis and comorbidities of COPD and factors associated with lung function Year: 2017 Borderline pulmonary hypertension was associated with reduced cardiac output during exercise in patients withconnective tissue diseases Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD Source: Eur Respir J 2016; 47:1365-1373 Year: 2016 Elevated pulmonary vascular resistance is associated with increased risk of death in IPF Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 Borderline pulmonary hypertension is associated with exercise intolerance and increased risk for acute exacerbation in patients with interstitial lung disease Source: International Congress 2018 – Pulmonary hypertension in lung diseases and the role of the right ventricle Year: 2018 Oxygen pulse slope analysis during exercise testing identifies patients with systemic sclerosis at a possible risk for developing pulmonary vasculopathy Source: Annual Congress 2013 –Clinical exercise physiology Year: 2013 Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients Source: ERJ Open Res, 5 (2) 00021-2019; 10.1183/23120541.00021-2019 Year: 2019 Elevated pulmonary vascular resistance predicts mortality in COPD patients Source: Eur Respir J, 58 (2) 2100944; 10.1183/13993003.00944-2021 Year: 2021 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 COPD phenotypes not linked to increased risk of coronary heart disease Source: International Congress 2019 – Comorbidities galore in respiratory patients Year: 2019 Distance assessment of the risk of pulmonary hypertension associated with connective tissue diseases: do biomarkers help? Source: Virtual Congress 2021 – Pulmonary hypertension in the COVID-19 pandemic and beyond Year: 2021 The role of cardiopulmonary exercise testing in assessment of the severity of patients with PAH associated with congenital heart disease. Source: International Congress 2019 – Pulmonary hypertension: clinical Year: 2019 NT-pro-BNP levels are independent of exercise in pulmonary hypertension Source: Annual Congress 2007 - Pulmonary hypertension in the clinic Year: 2007 Early risk prediction in idiopathic versus connective tissue disease-associated pulmonary arterial hypertension: call for a refined assessment Source: ERJ Open Res, 7 (3) 00854-2020; 10.1183/23120541.00854-2020 Year: 2021 Increased CCL18 serum levels in patients with pulmonary fibrosis which reflect disease severity Source: Eur Respir J 2005; 26: Suppl. 49, 21s Year: 2005 Ambrisentan therapy for patients with PAH associated with connective tissue disease (PAH-CTD): one year follow-up Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Sitaxsentan improves 6MW and hemodynamics in patients with pulmonary arterial hypertension (PAH) related to connective tissue disease (CTD) Source: Eur Respir J 2005; 26: Suppl. 49, 564s Year: 2005 Epicardial fat mass is increased in patients with COPD: A non-invasive cardiovascular marker in a high risk population Source: Annual Congress 2012 - Functional imaging in pulmonary oncology and COPD. Radiation dose in chest CT: survey and real life Year: 2012